(Q37690745)

22 August 2017

1 reference

title

Update on emerging drug therapies for systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

22 August 2017

main subject

0 references

author name string

Chi Chiu Mok

series ordinal

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

15

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

53-70

1 reference

Emerging drug therapies for systemic lupus erythematosus

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Treatment of severe proliferative lupus nephritis: the current state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Therapeutic options for resistant lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate mofetil in lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Lupus nephritis: treatment with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate therapy of SLE membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Lupus erythematosus with leflunomide: induction or reactivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Leflunomide-induced subacute cutaneous lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

An open study of dehydroepiandrosterone in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Intravenous immunoglobulin therapy and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Intravenous immunoglobulin and the kidney--a two-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

The type I interferon system in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

The role of immune ablation and stem cell transplantation in severe SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Autoimmunity following haematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Cell therapy for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903535878

10.1517/14728210903535878

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference